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Pancreas • Volume 00, Number 00, Month 2016was found in the obesity subcohort. Pancreatic fat fraction correlated to In-
sulin Secretion Sensitivity Index-2 and Homeostatic Model Assessment of
Insulin Resistance in simple regression; however, when using adjusted re-
gression and correcting for BMI-SDS and other fat compartments, PFF
correlated only to visceral adipose tissue and fasting glucose. Highest
levels of PFF were found in subjects with obesity and MetS.
Conclusions: In adolescents with obesity, PFF is elevated and associated
to MetS, fasting glucose, and visceral adipose tissue but not to beta-cell
function, glucose tolerance, or BMI-SDS. This study demonstrates that
conclusions regarding PFF and its associations depend on the body mass
features of the cohort.
Key Words: pancreatic fat, pediatric obesity, beta-cell function,
metabolic syndrome, body mass index-standard deviation score
(Pancreas 2016;00: 00–00)T he prevalence of pediatric obesity and type 2 diabetes mellitushas increased in recent decades.1,2 Obesity-related metabolic
complications are associated with distribution and amount of
lipids stored in adipose tissue compartments.3 Accumulation of
lipids in subcutaneous adipose tissue (SAT) is complemented with
storage in visceral adipose tissue (VAT) and other ectopic sites
such as the liver and pancreas.3 Pancreatic fat fraction (PFF) can
be measured by magnetic resonance imaging (MRI) and increase
with body mass index (BMI) both in adults4 and adolescents.5,6 In
addition, elevated PFF has been associated with age, male sex, and
Hispanic ethnicity.7,8
Pancreatic fat is located in close proximity to insulin-
secreting beta-cells and is a part of the total ectopic fat deposition,
which implies that it could potentially be associated to both beta-
cell function (BCF) and insulin resistance (IR). Indeed, pancreatic
fat has been connected to impaired BCF in both adults4,9 and
youth.10 In contrast, other previous studies have found no such re-
lationship.5–8,11 Furthermore, several studies report associations
between high PFF and IR as well as impaired glucose metabo-
lism.6,9,10,12 A gradual increase in PFF between subjects with nor-
mal glucose tolerance (NGT), impaired fasting glucose (IFG), and
impaired glucose tolerance (IGT) has been demonstrated.13 The
highest levels of PFF have been found in subjects with diabetes.9,14
The prevalence of MetS in adults has been estimated at ap-
proximately 20% to 30% and at 12% to 30% in adolescents.
2,15,16 In addition, elevated levels of PFF have been linked toMetS
in both adults12,17 and adolescents.5 Furthermore, disturbed levels
of proinsulin as well as the proinsulin-to-insulin (P/I) ratio have
been proposed as possible biomarkers of beta-cell dysfunction
and impaired glucose regulation. These biomarkers have also beenwww.pancreasjournal.com 1
Staaf et al Pancreas • Volume 00, Number 00, Month 2016associated to MetS18,19; however, their relation to PFF has yet not
been studied.
This study had 4 main objectives. These were to carefully
measure PFF in children and adolescents with and without obesity
and to 1. relate it to indices of BCF and IR; 2. explore a previously
reported correlation between PFF and MetS; 3. examine whether
PFF differs between subjects with NGTand IFG/IGT; and 4. study
the correlation between PFF and other body composition mea-
surements including MRI-based quantification of VAT, SAT, and
liver fat fraction (LFF) and BMI-standard deviation score (SDS).
The results and discussion sections are structured to follow the or-
der of these objectives.
MATERIALS AND METHODS
Study Population
This dual-center cross-sectional study was carried out at
Uppsala University Hospital, Sweden and Paracelsus Medical
University Hospital in Salzburg, Austria. Children and adoles-
cents (N = 125) aged 10 to 18 years and part of the beta-JUDO
(beta-cell function in JUvenile Diabetes and Obesity) cohort
(FP7-HEALTH-2011-two-stage, project number: 279153) were
included based on age. Subjects unable to comply with the MRI
and oral glucose tolerance test (OGTT) protocols were excluded.
Furthermore, 9 subjects were excluded because of missing PFF
or OGTT datasets, leaving 116 subjects with complete datasets
to be further analyzed. Ninety (44 females) subjects were charac-
terized with obesity (BMI-SDS ≥ 2.0) and 26 (12 females) as
nonobese (BMI-SDS < 2.0).20,21 The latter group is not denoted
controls because it includes both overweight and underweight
subjects. Examinations were harmonized between study centers.
Written parental and oral consent from children as well as ethical
approval from local ethics committees were obtained.
Anthropometric and Blood
Pressure Measurements
Height and weight were assessed by standardized and cali-
brated scales (Seca,Hamburg, Germany) and stadiometers (Uppsala:
Ulmer (Busse design); Salzburg: Seca). The BMI-SDS was calcu-
lated with Microsoft Excel add-in LMS Growth using WHO
growth report.21 Waist circumference was measured midway be-
tween the superior border of the iliac crest and lowest rib. Systemic
blood pressure was measured using a standardized clinical aneroid
sphygmomanometer (Uppsala: CAS 740; CAS Medical Systems,
Inc, Branford, Conn; Salzburg: Carescape V100; Dinamap
Technology/GE, Vienna, Austria).
Blood Sampling and Analyses
Blood was sampled at fasting using an intravenous stationary
catheter. Glucose, triacylglycerides (TG) and high-density lipo-
proteins (HDL) were analyzed according to local protocols. In
Uppsala, glucose was analyzed using an Architect c8000 instru-
ment (Abbott Diagnostics, Solna, Sweden) and by a Gluco-
quant Glucose-Kit (Roche Diagnostics, Mannheim, Germany) in
Salzburg. Uppsala quantified TG and HDL using an Architect
c800 instrument (Abbott Diagnostics) and in Salzburg an enzy-
matic photometric test (Modular Analytics System, P-Modul,
917; Roche Diagnostics) was used. Validation of analyses was
performed between the laboratories in Uppsala and Salzburg
using reference blood samples.
Selected samples underwent immediate centrifugation at
2500g for 10 minutes at 4°C, subsequently aliquoted, and frozen
at −80°C. Plasma was later used for central analyses of insulin,2 www.pancreasjournal.comproinsulin, and C-peptide in Uppsala. Single-plex enzyme-linked
immunosorbent assay kits for each analyte were used (Mercodia
AB, Uppsala, Sweden). Standardized control samples (Mercodia
AB) were used to control for interplate variability.
Oral Glucose Tolerance Test
The OGTTs were conducted as previously described.22 Sub-
jects were instructed to drink a 300-mL glucose solution (1.75 g
glucose per kilogram body weight; maximum 75 g glucose)
within approximately 5 minutes. Subsequently, blood samples
were obtained from a stationary venous catheter at predetermined
time points after the glucose challenge.
Definition ofMetabolic Syndrome and Prediabetes
The MetS was defined according to the International Diabe-
tes Federation consensus for children and adolescents.23 Prediabe-
tes was defined as IFG and/or IGT according to the American
Diabetes Association24 because of the same fasting glucose cutoff
level (≥5.6 mmol) as in MetS.
Beta-cell function and IR
To estimate BCF and IR, several indices were used. Homeo-
static model assessment (HOMA)-beta and P/I were derived from
fasting measurements.25,26 First-phase insulin secretion during
OGTTwas evaluated by insulinogenic index (IGI) using 15 and
30 minutes as well as both insulin and C-peptide in the numera-
tor.27 The area under the curve (AUC), calculated using the trape-
zoid rule, for glucose, insulin, and C-peptidewas used to represent
both total and dynamic secretory response for the entire OGTT
period. Dynamic AUC was calcuted as the AUC above baseline
(t=0). The BCF corrected for insulin sensitivity was assessed by
the oral disposition index (IGI  Matsuda index) and the insulin
secretion sensitivity index-2 (ISSI-2) ([AUCinsulin/AUCglucose] 
Matsuda index).10,26 The IR was assessed by HOMA-IR, 1/fasting
insulin, and by the Matsuda index.26,28
Magnetic Resonance Imaging
The MRI examinations were performed to determine PFF,
LFF, and volumes of abdominal VAT and SAT. All examinations
were performed using 1.5 Tesla clinicalMRI systems from Philips
Medical System (Best, The Netherlands). Uppsala used a Philips
Achieva system, whereas Salzburg used a Philips Ingenia system.
Uppsala served as core laboratory and developed and stan-
dardized the imaging protocol at both sites and performed all
image analyses.
Imaging was conducted in a supine position after a standard-
ized light meal in proximity to the OGTT, preferably on the same
day. All MRI assessments used water-fat imaging techniques dur-
ing breath hold. The pancreas scan was performed using surface
coils, and the LFF and VAT/SAT scans were performed using
the built-in body coils. The pancreas scan was tilted (−15 degrees
around the coronal direction) for better pancreas coverage.
For both pancreas and liver, thewater-fat image reconstruction
was performed using a multiresolution version of a previously de-
scribed method that uses a whole-image optimization approach.29
The reconstruction used the same TG spectrum model,30 a com-
mon R2* parameter, and a regularization parameter (μ = 10).
The water and fat image reconstruction was performed using the
last 5 echoes only because phase errors in the first echowere seen
to significantly affect the results.31,32 The first and last slices in
each volume were excluded from the analysis because the image
contrast in these slices differed.
An experienced operator performed the measurements using
manual segmentation. The segmentations were performed in the© 2016 Wolters Kluwer Health, Inc. All rights reserved.
Pancreas • Volume 00, Number 00, Month 2016 Pancreatic Fat and Associations in Pediatricswater images using the software ImageJ (version 1.42q, http://
rsbweb.nih.gov/ij/). To reduce the effect of partial volume between
the pancreas and surrounding adipose tissue, the pancreas bound-
ary was avoided, and the median fat fraction value in each seg-
mented volume of interest was used. For improved precision, 1
operator segmented each pancreas twice with approximately
1 month in between measurements. The averages of the 2 fat frac-
tion measurements were used as final estimate of PFF. Repeated
measurements of the whole cohort gave significantly different
mean values of 3.11% and 2.88% (P = 0.02). The SD between
the repeated measurements was on average 0.54 percentage
points. Details on examination of LFF, SAT, and VAT can be found
in the Supplemental Digital Content, Appendices A and B, http://
links.lww.com/MPA/A565.
Statistical Analyses
Data are presented as median and range or mean ± SD de-
pending on data distribution. Screening for normality was done
by Shapiro-Wilk test. Most parameters were not normally distrib-
uted, therefore nonparametric tests were applied: the Spearman
rank test (correlations) and Mann-Whitney U test (group differ-
ences). Normally distributed data were analyzed based on para-
metric tests: the Student t test (group differences).
Significant associations were further analyzed using adjusted
regression models, controlling for age and body composition. The
PFF was logarithm-transformed and 2 models were used. The first
(model A) included age and BMI-SDS. The second (model B) in-
cluded VAT, SAT, and LFF. Only parameters that were signifi-
cantly associated to PFF in simple regression, in the respective
subcohorts, were used as covariates in the 2 models. The associa-
tion between PFFandMetS was controlled for by VATusing anal-
ysis of covariance. All statistical procedures were determined
before the analyses started. Statistical analyseswere performed using
GraphPad Prism 6.0c (GraphPad Software Inc, La Jolla, Calif )
and Statistica 12 (Statsoft Inc, Tulsa, Okla). The level of signifi-
cance was P < 0.05.RESULTS
Basic Characteristics
Characteristics of study subjects are presented in Table 1. As-
sociations between PFF and other parameters are presented in
Table 2, with separate analyses performed for the whole cohort
as well as the subcohorts (subjects with and without obesity, re-
spectively). Age and sex ratios did not differ between the
subcohorts. Age, BMI-SDS, and PFF did not differ between
sexes. All fat compartments measured were significantly higher
in subjects with obesity (Table 1). The PFF was not related to
age in this cohort (Table 2).
Pancreatic Fat Fraction and BCF
Fasting insulin, proinsulin, and C-peptide levels were signif-
icantly elevated in subjects with obesity (Table 1). In thewhole co-
hort, these parameters were positively correlated to PFF in simple
regression models; however, all correlations except fasting
C-peptide lost significances in subjects with obesity (Table 2). Al-
though the association between ISSI-2 and PFF was negative, a
positive correlation was found regarding AUCproinsulin in the
whole study group. The ISSI-2 was also significantly correlated
to PFF in subjects with obesity; however, significance was lost
in adjusted regression analysis (Table 2). Regarding other param-
eters of insulin secretion and BCF, no associations were found.© 2016 Wolters Kluwer Health, Inc. All rights reserved.Pancreatic Fat Fraction and IR
Subjects with obesity had higher IR than nonobese subjects
(Table 1). Furthermore, IR calculated by Matsuda index, HOMA-
IR, and 1/fasting insulin were all associated to PFF in the whole
cohort (Table 2). When only obese individuals were examined, a
significant relationship between HOMA-IR and PFF was found
in the simple regression model (Table 2), but no significant corre-
lations were found in adjusted regression models.
Pancreatic Fat Fraction and MetS
To investigate association between PFF and MetS, the study
population was divided into 3 groups: subjects without obesity
(group 1), subjects with obesity but without MetS (group 2), and
subjects with obesity and MetS (group 3). The groups did not dif-
fer with regard to age or sex, and groups 2 and 3 did not differ with
regard to BMI-SDS (data not shown). As depicted in Figure 1, a
gradual increase in PFF was shown between groups. Group 1
(n = 26): 1.05 (−0.4–3.3)%; group 2 (n = 66): 2.2 (−0.6–11.8)%;
and group 3 (n = 24): 3.65 (1.2–14.6)% (1 vs 2: P = 0.002; 2 vs
3: P = 0.016). In group 3, IR, fasting insulin, and proinsulin levels
were also significantly elevated (data not shown). Systolic blood
pressure and triglyceride levels were elevated in subjects with
obesity, whereas no difference in HDL or fasting glucose levels
was detected between subjects with and without obesity (Table 1).
After adjustment for VAT, the association of PFF and MetS
had a P value of 0.051 between the groups with obesity and
0.058 between all groups.
Pancreatic Fat Fraction and Glucose Metabolism
Fasting glucose was associated with PFF in subjects with
obesity (Table 2). Subjects with IFG had higher PFF compared
with subjects with NGT (3.4% vs 2.2%, P = 0.026). Moreover,
a trend was observed between PFF and the 2-hour glucose level
in obese children (Table 2). The PFF did, however, not differ be-
tween obese NGT and obese prediabetic subjects (IFG and IGT)
(P = 0.105), and no difference was detected between obese IFG
and IGT (P = 0.276). In subjects without obesity, a negative corre-
lation between PFF and fasting glucose was observed (Table 2).
When adjusted regression modeling was used, only PFF and
fasting glucose in subjects with obesity remained significantly
correlated (r = 0.243, P = 0.020).
Pancreatic Fat Fraction, Other Fat Compartments,
and BMI-SDS
In the whole cohort, PFF was positively correlated to VAT,
SAT, and liver fat (Table 2). However, VATwas the only signifi-
cant parameter in adjusted models (model A: r = 0.289,
P = 0.021; model B: r = 0.340, P = 0.027). In addition, when sub-
jects with obesity were examined, only VAT showed correlation to
PFF in simple regression models. When examining ectopic fat de-
position in the pancreas and liver, a positive correlation was found
in subjects without obesity. In subjects with obesity, no association
was found (Table 2) (Fig. 2). The BMI-SDS correlated to amount
of PFF in the whole cohort and in subjects without obesity; how-
ever, no correlation between BMI-SDS and PFF in subjects with
obesity was found (Table 2) (Fig. 3).
Cohort-Dependent Results
Associations between PFF and other parameters were fre-
quently found dependent on the cohort examined (Table 2). Com-
paring thewhole cohort with the obesity subcohort, 12 associations
to PFF were differently correlated. These differences were foundwww.pancreasjournal.com 3
TABLE 1. Descriptive Data and Group Comparison Between Children and Adolescents Without Obesity (Nonobese) and With
Obesity (Obese)
Nonobese, n = 26 Obese, n = 90
Females, n (%) 12 (46%) 44 (49%)
Age, y 13.8 ± 1.9 14.1 ± 2.2
BMI-SDS 0.68 ± 1.2 3.0 ± 0.5*
Fat distribution
Pancreatic fat fraction, % 1.1 (−0.4–7.1) 2.4 (−0.6–14.6)†
VAT, cm3 558.0 (99.0–1718.4) 1413.0 (796.2–3842.5)*
SAT, cm3 1753.0 (170.3–6861.7) 6905.0 (2910.0–12,393.0)*
Liver fat fraction, % 1.6 (0.6–49.9) 5.8 (1.3–45.6)*
Beta-cell function
Fasting insulin, pmol/L 50.1 (8.7–213.4) 119.3 (32.2–392.3)*
Fasting proinsulin, pmol/L 7.3 (2.7–19.9) 19.8 (2.7–73.0)*
Fasting C-peptide, pmol/L 482.6 (105.1–1189.0) 815.6 (331.0–2089.0)*
HOMA-beta 88.5 (22.8–482.7) 227.8 (40.8–1134.9)*
IGI 30 min (insulin) 25.4 (3.6–95.1) 41.3 (8.3–157.9)‡
oDI 2638.5 (833.8–7831.4)‡ 1735.5 (308.7–9003.5)
Insulin sensitivity
HOMA-IR 1.7 (0.3–6.5) 4.0 (0.9–15.0)*
Matsuda index 94.5 (37.6–459.5)* 42.9 (10.1–139.0)
MetS, n (%) 0 24 (27%)
Blood pressure
SBP, mm Hg 112.2 ± 7.0 122.2 ± 11.5†
DBP, mm Hg 67.4 ± 6.2 68.0 ± 10.6
Lipid metabolism
TG, mmol/L 0.6 (0.4–1.2) 1.1 (0.4–4.5)*
HDL-C, mmol/L 1.3 (1.0–2.8) 1.2 (0.7–2.5)
Glucose metabolism
IGT, n (%) 2 (8%) 17 (19%)
IFG, n (%) 6 (23%) 10 (11%)
Fasting glucose, mmol/L 5.1 ± 0.6 5.0 ± 0.7
Values are mean ± SD or median (range).
*P < 0.0001.
†P < 0.001.
‡P < 0.01.
DBP indicates diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; oDI, oral disposition index; and SBP, systolic blood pressure.
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glucose metabolism, and fat compartments (Table 2).DISCUSSION
Fat accumulation in the pancreas could potentially have an
effect on insulin-producing beta-cells, both directly through
lipotoxicity mediated by the release of free fatty acids and indi-
rectly through activation of inflammatory pathways.7 Indeed,
PFF has been shown to correlate with pancreatic TG content33
and circulating free fatty acids.7 However, whether pancreatic
adipocyte infiltration reflects intra-islet fat content and whether
adipose tissue within the pancreas has a profound effect on insulin-
secreting beta-cells remain unclear.10 When we in this study
compared pediatric subjects with and without obesity, significant
differences could be found in PFF as well as in parameters of
BCF and IR (Table 1). However, when simple regression analyses
were performed, only few parameters of BCF showed an associa-
tion to PFF (Table 2). The ISSI-2 correlated to PFF in subjects
with obesity, confirming previous results in youth.10 Cohen et al104 www.pancreasjournal.cominvestigated BCF and IR in juveniles with PFF absent and PFF
present, respectively. The PFF-present group had impaired BCF
and elevated IR10; however, only 29% of the subjects were found
in this group, which must be considered when interpreting the re-
sults. Indeed, Cohen et al10 showed a relation between PFF and
ISSI-2 in a group comparison, but when adjusting for BMI-SDS
and VAT, no correlation between PFF and any indices of BCF re-
mained significant in this study. This also agrees with recently
published data in adults.11 These previous findings and our con-
curring data lead us to conclude that PFF is not directly associated
to BCF in childhood.
Interestingly, PFF correlated to fasting proinsulin and
AUCproinsulin in the whole cohort, indicating that elevated PFF
could potentially contribute to beta-cell stress and disturbed intra-
cellular insulin processing. Proinsulin has previously been related
to beta-cell dysfunction.18 However, when analyzing subcohorts
separately, no correlations remained indicating that the positive
correlations may be due to group differences. In addition, in the
whole cohort, PFF was related to IR verifying previous results
of ectopic fat relating to IR.9,10,12 Nonetheless, in obese children,© 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Simple Spearman Rank Correlations Between Pancreatic fat fraction and Phenotype Data
Pancreatic fat fraction
Whole Study Group (n = 116) Obese (n = 90) Nonobese (n = 26)
Simple Regression
rSpearman P rSpearman P rSpearman P
Age −0.059 0.526 −0.074 0.486 −0.181 0.377
BMI-SDS 0.276 0.003 0.021 0.841 0.399 0.043
Beta-cell function
IGI 15 minOGTT insulin 0.091 0.345 0.016 0.884 −0.118 0.600
IGI 30 minOGTT insulin 0.106 0.266 0.017 0.875 0.013 0.951
IGI 15 minOGTT c-peptide 0.056 0.564 −0.023 0.854 −0.076 0.737
IGI 30 minOGTT c-peptide 0.038 0.691 −0.046 0.670 0.087 0.672
HOMA-beta 0.183 0.053 −0.004 0.969 0.177 0.397
oDI −0.126 0.194 −0.133 0.232 0.278 0.178
ISSI-2 −0.242 0.012 −0.301 0.006 0.311 0.131
AUC insulin 0.177 0.057 0.074 0.490 −0.211 0.302
AUC proinsulin 0.183 0.050 0.094 0.378 −0.278 0.169
AUC c-peptide 0.170 0.068 0.063 0.555 −0.134 0.516
Dynamic AUC insulin 0.159 0.088 0.050 0.639 −0.159 0.439
Dynamic AUC proinsulin 0.157 0.093 0.076 0.475 −0.288 0.153
Dynamic AUC c-peptide 0.098 0.296 −0.020 0.852 −0.097 0.639
P/I fasting −0.022 0.814 −0.062 0.561 −0.035 0.866
P/I 15 minOGTT 0.092 0.328 0.074 0.489 −0.173 0.409
P/I 30 minOGTT −0.052 0.577 −0.056 0.602 −0.227 0.265
Insulin sensitivity
HOMA-IR 0.284 0.002 0.211 0.047 −0.219 0.282
Matsuda index −0.271 0.005 −0.210 0.057 0.260 0.209
1/Insulin −0.268 0.004 −0.179 0.091 0.116 0.574
MetS components
Waist circumference 0.312 0.001 0.108 0.327 0.308 0.127
Systolic blood pressure 0.210 0.026 0.037 0.734 0.279 0.168
Diastolic blood pressure 0.124 0.191 0.150 0.168 0.008 0.968
Triglycerides 0.193 0.038 0.019 0.860 0.098 0.632
HDL −0.122 0.196 −0.173 0.105 0.209 0.316
Fasting glucose 0.107 0.257 0.290 0.006† −0.527 0.006
Glucose metabolism
Glucose 120 min 0.155 0.099 0.166 0.120 −0.088 0.675
Fasting insulin 0.268 0.004 0.179 0.092 −0.114 0.578
Fasting proinsulin 0.237 0.011 0.131 0.218 −0.202 0.324
Fasting C-peptide 0.325 <0.001 0.223 0.035 0.100 0.627
Fat compartments
VAT 0.414 <0.001*† 0.223 0.034 0.472 0.015
SAT 0.272 0.003 0.041 0.701 0.294 0.145
Liver fat 0.273 0.003 0.033 0.758 0.480 0.013
Bold letters indicate significant univariate correlations.
*†Significant results after controlling for significant covariates using models A and B, respectively. Model A includes age and BMI-SDS and model B
includes VAT, SAT, and liver fat.
Pancreas • Volume 00, Number 00, Month 2016 Pancreatic Fat and Associations in Pediatricsonly HOMA-IR remains significant, and in adjusted regression
models, no significant correlations were found (Table 2). There-
fore, we conclude that PFF is not a marker of proinsulin secretion
or the result of IR in adolescence. Other depots such as visceral fat
and hepatic fat are likely to be more strongly associated to IR.6
Obesity is associated with increased risk of MetS.34 In the
present study, PFF was significantly higher in subjects with obe-
sity and MetS, confirming previous studies both in adults12 and© 2016 Wolters Kluwer Health, Inc. All rights reserved.adolescents.5 However, Lee et al12 used computed tomography
to quantify PFF in adults, whereas Maggio et al5 included only
5 adolescents with MetS. We found that both PFF and VATwere
elevated in subjects with obesity and MetS and related to each
other. The PFF was not independently associated to MetS when
adjusting for VAT (P = 0.051), indicating that VAT constitutes a
link. On the other hand, we acknowledge a very strong trend be-
tween PFF and MetS, independently of VAT, that challengeswww.pancreasjournal.com 5
FIGURE 1. Pancreatic fat fraction and MetS. The graph
demonstrates PFF in nonobese, obese non-Mets, and obeseMetS
subjects using a Tukey plot. *P = 0.0029, #P = 0.0156.
FIGURE 3. Scatter plot and regression lines of BMI-SDS and
pancreas fat when considering the different groups. Nonobese:
full circles and full line. Obese: open circles, dashed line.Whole study
group: dotted line.
Staaf et al Pancreas • Volume 00, Number 00, Month 2016previous findings5 and warrants further investigations. Generally,
subjects with MetS have an increased risk of type 2 diabetes
mellitus.34 In adults, PFF has been shown to be highest in subjects
with diabetes.14 Recent pediatric studies have demonstrated that
prediabetic subjects have higher PFF.6,35 However, when adjusted
regression analyses were performed by Pacifico et al,6 only liver
fat remained significantly correlated to prediabetes. In the present
study, no significant relationship between PFFand IGTwas found;
however, we demonstrate a positive correlation between PFF and
fasting plasma glucose as well as PFFand IFG, which need further
longitudinal investigation in larger cohorts with regard to causality
and pathophysiological impact.
We found that LFF was approximately 4 times higher and
PFF at least 2 times higher in subjects with obesity (Table 1). Pre-
vious studies have reported a weak or nonexisting correlation be-
tween ectopic fat deposition in the pancreas and liver.5,9 Here, weFIGURE 2. Scatter plot and regression lines of liver fat and pancreas
fat when considering the different groups. Nonobese: full circles
and full line. Obese: open circles, dashed line. Whole study group:
dotted line.
6 www.pancreasjournal.comobserve a correlation between these depots in subjects without
obesity, suggesting that early deposition of ectopic fat is not organ
specific. Indeed, PFF has also previously been associated to he-
patic steatosis in adults.36 We also discovered a positive correla-
tion in the whole cohort, but interestingly not within the obesity
subcohort (Fig. 2), implying that once obesity is overt, ectopic
fat deposition is more organ selective, possibly because of genetic
factors.37 Our results are in agreement with data reported by
Pacifico et al.6 Furthermore, we report that PFF and VAT show a
significant association, which has also been demonstrated previ-
ously.7 Given the close proximity between these depots, this asso-
ciation was expected, but whether VAT is the main cause of PFF
still remains to be elucidated.
Previously, a positive correlation between BMI and PFF was
observed.38 Interestingly, in the present study, PFF is higher in
subjects with obesity compared with subjects without obesity,
yet in the obesity subcohort, no association between PFF and
BMI-SDS was established (Table 2) (Fig. 3) despite the relatively
wide range of BMI-SDS in this subcohort. This indicates that
once obesity is present in adolescence, accumulation of pancreas
fat is driven by other factors than total body fat. One relatively
small-sized pediatric study has previously reported a difference
in PFF between subjects with and without obesity; however, the
correlation between PFF and BMI-SDS in regression analysis
has not been investigated.5 Furthermore, the present study demon-
strates that the associations of PFF to other parameters in simple
regression models are highly dependent on BMI characteristics
of the cohort studied. This could serve as explanation of previ-
ously reported conflicting results regarding the association be-
tween PFFand estimates of BCFand IR in heterogeneous cohorts.
Multiple techniques can be applied to quantify adipose tis-
sue. With the use of MRI, PFF can accurately be determined
and studied in relation to metabolic abnormalities.3 Previously,
PFF has been measured using computed tomography,12 magnetic
resonance spectroscopy,9,11 and MRI.4,5,10,39 Among these, MRI
is advantageous because it allows analysis of lipid-specific signals
from a large section of the pancreas without using ionizing radia-
tion. The PFF varied between approximately 0% (absent) to 15%
in this study. Previously reported amounts of PFF differ; in pedi-
atric subjects, maximum values of 7% to 14.4% have been re-
ported,5,10 and adults show similar maximum values.8,38–40 One© 2016 Wolters Kluwer Health, Inc. All rights reserved.
Pancreas • Volume 00, Number 00, Month 2016 Pancreatic Fat and Associations in Pediatricssingle study, which used magnetic resonance spectroscopy, re-
ported maximum PFF of more than 50%.9
This study is one of the largest examining PFF with MRI in
children, but results must be interpreted with some limitations in
mind. Subjects were recruited at 2 European sites; however, all ex-
aminations were harmonized and carried out according to stan-
dard operations procedures. Furthermore, in both subcohorts the
range in BMI-SDS was relatively wide (Fig. 3). Because PFF did
not correlate with age in either subcohort, puberty was not taken
into consideration. Other limitations are that no clamps were con-
ducted, which is the criterion-standard method to assess insulin
secretion and resistance and that ethnicity was not controlled for.
We conclude that adolescent subjects with obesity have ele-
vated PFF that is not associated to BCF or IR. Rather, PFF is as-
sociated to MetS and VAT. This association study also identified
an interesting association to fasting glucose level that warrants fur-
ther evaluation and demonstrates that conclusions regarding PFF
and its associations are highly dependent on BMI-SDS of the
studied cohort.
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